Minted: - / 5000

1740 Fezolinetant
fec270a2862881f57df398e07e47add97197edcf983004d3fe689c91600c0331

Properties

Background

Blue
Bottle

Purple
Cap

Light blue
Syringe

Blue
Bubbles
No
Drops
No
Label
Drop

Chemistry

Formula
C16H15FN6OS
Carbon
16
Polarity
Neutral

Fezolinetant (; former developmental code name ESN-364) is a small-molecule, orally active, selective neurokinin-3 (NK₃) receptor antagonist which is under development by Ogeda (formerly Euroscreen) for the treatment of sex hormone-related disorders. As of May 2017, it has completed phase I and phase IIa clinical trials for hot flashes in postmenopausal women. Phase IIa trials in polycystic ovary syndrome patients are ongoing. In April 2017, it was announced that Ogeda would be acquired by Astellas Pharma.

From Wikipedia, the free encyclopedia. License: CC BY-SA.